October 21, 2026 Media Coverage from ARCH Venture Partners | Share ARCH’s Bob Nelsen named to Forbes’ 2026 list of America’s most successful living optimists
October 19, 2026 Media Coverage from ARCH Venture Partners | Share ARCH-backed City Therapeutics closes $230 million IPO to drive RNAi therapeutics
August 25, 2026 Media Coverage from ARCH Venture Partners | Share ARCH-backed Sentivera launches with $1.5B to target inflammatory diseases
June 17, 2026 Media Coverage from ARCH Venture Partners | Share Kardigan raises $400M in IPO to fund three clinical-stage cardiovascular programs
June 11, 2026 Media Coverage from ARCH Venture Partners | Share ARCH-backed SonoThera secures Series B funding to advance safer gene therapies
June 10, 2026 Media Coverage from ARCH Venture Partners | Share Cancer-focused Parabilis Medicines sets biotech IPO record with $670M offering
May 26, 2026 Media Coverage from ARCH Venture Partners | Share Vaccine company to be acquired by Lilly for up to $1.55 billion
May 1, 2026 Media Coverage from ARCH Venture Partners | Share Neuropsychiatry company Seaport Therapeutics debuts on public market with $225M
April 28, 2026 Media Coverage from ARCH Venture Partners | Share ARCH-backed Paradigm Health partners with FDA to provide technology platform for real-time clinical trial monitoring
April 11, 2026 Media Coverage from ARCH Venture Partners | Share The San Francisco Business Times honors ARCH’s Carol Suh on 40 Under 40 Class of 2026
February 27, 2026 Media Coverage from ARCH Venture Partners | Share Generate Biomedicines goes public with $400M to accelerate AI-driven drug discovery
February 19, 2026 Media Coverage from ARCH Venture Partners | Share ARCH’s Carol Suh named to National Venture Capital Association’s 2026 List of Rising Stars
